blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP3934649

EP3934649 - METHODS OF TREATING DISEASE WITH LEVOKETOCONAZOLE [Right-click to bookmark this link]
StatusExamination is in progress
Status updated on  22.03.2024
Database last updated on 15.06.2024
FormerRequest for examination was made
Status updated on  10.12.2021
FormerThe international publication has been made
Status updated on  11.09.2020
Most recent event   Tooltip17.04.2024New entry: Reply to examination report 
Applicant(s)For all designated states
Strongbridge Dublin Limited
900 Northbrook Drive, Suite 200
Trevose, Pennsylvania 19053 / US
[2022/02]
Inventor(s)01 / COHEN, Fredric
900 Northbrook Drive Suite 200
Trevose, Pennsylvania 19053 / US
[N/P]
Former [2022/02]01 / COHEN, Fredric
Trevose, Pennsylvania 19053 / US
Representative(s)Sagittarius IP
Marlow International
Parkway
Marlow SL7 1YL / GB
[N/P]
Former [2022/02]Gibson, Mark
Sagittarius IP
Marlow International
Parkway
Marlow SL7 1YL / GB
Application number, filing date20766266.902.03.2020
[2022/02]
WO2020US20644
Priority number, dateUS201962813399P04.03.2019         Original published format: US 201962813399 P
[2022/02]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2020180784
Date:10.09.2020
Language:EN
[2020/37]
Type: A1 Application with search report 
No.:EP3934649
Date:12.01.2022
Language:EN
The application published by WIPO in one of the EPO official languages on 10.09.2020 takes the place of the publication of the European patent application.
[2022/02]
Search report(s)International search report - published on:US10.09.2020
(Supplementary) European search report - dispatched on:EP20.10.2022
ClassificationIPC:A61K31/496, A61K31/155, A61P5/46, A61P43/00, A61K45/06
[2022/47]
CPC:
A61K45/06 (EP,IL,KR); A61K31/497 (IL,US); A61K31/496 (EP,IL,KR);
A61K31/155 (EP,IL,KR,US); A61P43/00 (EP); A61P5/38 (KR);
A61P5/46 (EP); A61K2300/00 (IL,KR) (-)
C-Set:
A61K31/155, A61K2300/00 (EP);
A61K31/496, A61K2300/00 (EP)
Former IPC [2022/02]A61K31/496, A61K31/155
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2022/02]
TitleGerman:VERFAHREN ZUR BEHANDLUNG VON KRANKHEITEN MIT LEVOKETOCONAZOL[2022/02]
English:METHODS OF TREATING DISEASE WITH LEVOKETOCONAZOLE[2022/02]
French:PROCÉDÉS DE TRAITEMENT D'UNE MALADIE AVEC DU LÉVOKÉTOCONAZOLE[2022/02]
Entry into regional phase23.09.2021National basic fee paid 
23.09.2021Search fee paid 
23.09.2021Designation fee(s) paid 
23.09.2021Examination fee paid 
Examination procedure23.09.2021Examination requested  [2022/02]
28.04.2023Amendment by applicant (claims and/or description)
20.03.2024Invitation to indicate the basis for amendments (Time limit: M01)
16.04.2024Reply to an invitation to indicate the basis for amendments
Fees paidRenewal fee
11.03.2022Renewal fee patent year 03
23.03.2023Renewal fee patent year 04
27.03.2024Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[I]WO2016048984  (CORTENDO AB PUBL [US]) [I] 1-15 * claims 1-29 * * abstract * * the whole document *;
 [T]  - FLESERIU MARIA ET AL, "Levoketoconazole: a novel treatment for endogenous Cushing's syndrome", EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, GB, (20210628), vol. 16, no. 4, doi:10.1080/17446651.2021.1945440, ISSN 1744-6651, pages 159 - 174, XP055969224 [T] 1-15 * page 162, column r, paragraph 2 * * the whole document *

DOI:   http://dx.doi.org/10.1080/17446651.2021.1945440
International search[A]US2018153883  (MARIN PER [SE]) [A] 1, 3, 10/1, 10/3, 11/10/1, 11/10/3, 14/3, 15/14/3, 16/14/3, 17/3 * ; entire document *;
 [Y]WO2018106907  (NOVATARG INC [US]) [Y] 1, 3, 10/1, 10/3, 11/10/1, 11/10/3, 14/3, 15/14/3, 16/14/3, 17/3 * ; paragraphs [0017], [0029], [0133], [0321] *;
 [Y]US2018338971  (KOZIOL THEODORE RICHARD [US]) [Y] 11/10/1, 11/10/3 * ; abstract; paragraph [0008] *;
 [Y]  - ROSSI, K et al., "Phase 3 Trial of Endogenous Cushing's Syndrome Treatment Meets Primary Endpoint", (20180813), pages 1 - 2, URL: https://www.mdmag.com/medical-news/phase-3-trial-endogenous-cushings-syndrome-treatment-meets-primary-endpoint, XP055735587 [Y] 1, 3, 10/1, 10/3, 11/10/1, 11/10/3, 14/3, 15/14/3, 16/14/3, 17/3 * ; first page, first, fourth and last paragraphs *
 [PX]  - FLESERIU, M et al., "Results From the Phase 3 Multicenter SONICS Study of Levoketoconazole: Subgroup Analysis of Cushing's Syndrome Patients With Diabetes Mellitus", Endocrine Society Annual Meeting, (20190326), XP055847542 [PX] 1, 3, 10/1, 10/3
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.